Action 27. Mobilize their networks and work with communities to help build treatment literacy, generate demand, and expand access to ARVs among children.
Action 34. Increase efforts to share information on the roll-out of new paediatric formulations, including lessons learned.
Paediatric HIV & TB : Rome Action Plan
Identify and facilitate the most suitable financial incentive for a given product included in PADO list, possibly including one or more of the following:
Support to development upon timely achievement of key milestones
Advance market commitments.
Seek and direct funding to support the additional clinical research required to inform development and use of PADO priority products.
With the support of Unitaid, partner with Janssen and generic manufacturers to develop andregister DRV/r 120/20 mg by Q4 2020.
Manufacture new PADO priority pediatric ARV products “at risk” such that the new product isavailable for supply at time of approval/tentative approval/prequalification, including validation of manufacturing process during regulatory review.
Support catalytic procurement of all or part of initial validation batches from manufacturers suchthat product availability is not delayed once approval or tentative approval is achieved.
Incentivize commercialization of new pediatric ARV products “at risk” to accelerate introductionand scale up of new paediatric ARV product such that product is available at time ofapproval/tentative approval/prequalification.